Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
about
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightRole of occult hepatitis B virus infection in chronic hepatitis CPathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogenCannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis CPNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients.Pediatric non-alcoholic fatty liver disease: New insights and future directionsInsulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progressionMK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Association between complement C3 and prevalence of fatty liver disease in an adult population: a cross-sectional study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) cohort study.Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver TransplantationRole of genetic polymorphisms in hepatitis C virus chronic infection.PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patientsThe Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV CoinfectionChronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection.Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population.TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection.Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
P2860
Q26752583-F998232B-2FEE-428B-A830-52DC9F9BE4DEQ26823538-649FD90E-CCAC-4900-92DC-8D86C02881B1Q26861095-AFF2FB61-73DB-4E93-88B7-462ED5878514Q28539814-0A0FCE2A-C4AD-4549-93BA-C5F3D75A9216Q30418176-DF4ECB84-C4B9-4452-9E6D-2EBAA8992613Q33563887-E5A42E9D-7775-448A-B11B-8BA66F25C8EEQ34263370-7E5A3C48-688B-46E7-BED3-9FE2D64BB123Q34411907-DAF3223D-2F2F-4E5E-B642-3411799F5020Q34420891-3D5F03BF-EF40-4BCD-9554-A2858C2B0138Q35346715-AA0971E7-ABB5-46BD-8837-64B69B2CCC90Q35667877-85B70DFD-0C24-4D60-B413-7C61B1162580Q35779058-787D8D70-D92D-4432-80B3-A16A9A732C04Q35813637-03D5E60B-18B4-4404-9E03-8F65890E1714Q35849638-70E9A74E-79BB-4A7B-90D2-E32E0FAF5E93Q38157936-E6B2D6E2-1F3E-4CFD-8CCB-897507037893Q38180333-EEB38C46-B274-41CC-8EBC-83BC93261EC5Q38193198-2EC7750A-74C8-41EB-95C8-0A7803CFF1E5Q38233860-59B1E5D0-D283-4E5A-8E94-09EDCEFF9F80Q38235178-175C121D-7BFA-4F56-B142-E0F9D5403D72Q38237281-2293FBAC-0DBC-41EC-A61C-03373F818540Q38848095-9DC16F0B-B7A1-46EB-96F8-F8F9B8F733BFQ40124776-6CEEF7CC-4C28-4713-9BE1-F35834461DF5Q40482870-54D60742-AF13-4EFE-814C-F9C6FC636659Q41221366-F3BB6C6F-896B-4951-A7A1-853A1D7BCFDFQ41549262-E5EB3746-094D-4183-9176-6BD50FB598EFQ42153080-85BCE576-5DE3-42C6-ADB6-499171558AB9Q42245958-F572F9AD-4FE4-49F3-B541-32777F792EF1Q42255783-CE88B3C7-2B51-4B74-9287-4A4283713F2DQ47121548-A323AD7A-A6CE-4951-B448-A7C03558E104Q51172839-1E5A17CE-14C5-4B2C-BA36-CEECD0B74251
P2860
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@en
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@nl
type
label
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@en
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@nl
prefLabel
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@en
Abdominal fat interacts with P ...... atosis in chronic hepatitis C.
@nl
P2093
P2860
P50
P356
P1476
Abdominal fat interacts with P ...... eatosis in chronic hepatitis C
@en
P2093
E Miraglia del Giudice
L E Adinolfi
P2860
P304
P356
10.1111/JVH.12053
P577
2013-01-07T00:00:00Z